ClinicalTrials.gg
CompletedNCT03133429MERUpdated Nov 19, 2019

Clinical Study to Evaluate the Safety and Effectiveness of MER® Stents in Carotid Revascularisation.

An interventional study of MER in Carotid Artery Stenosis, sponsored by Balton Sp.zo.o.. Completed at 4 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-19.

Sponsored by Balton Sp.zo.o. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Carotid Stenosis with a site in Poland — 4 open to participants now, 6 under way, none of them phase 3. Carotid Stenosis · Poland.

Started
2016
the only one that year
No phase
5 of 10
1 open now
Registered
3rd of 10
by date
Lead sponsor
1 of 10
Balton Sp.zo.o.

Among the 10 studies in Carotid Stenosis with a site in Poland, this one is the only one that started in 2016, is one of 5 with no phase, and was the 3rd registered.

Carotid Stenosis

369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.

Browse Carotid Stenosis studies →

Open to participants now

4 of the 10 studies in Carotid Stenosis with a site in Poland are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Carotid Stenosis with a site in Poland, or all of them as a file.
02

Study summary

The aim of the study is to confirm, whether the MER® stent can be used, without limitations, for the endovascular carotid stenosis treatment in daily clinical practice. Eligible patients will undergo the procedure of the common or internal carotid artery stenting using MER® with proximal or distal neuroprotection.

Read the detailed description

MER® stent will be implanted in eligible patients with common and internal carotid stenosis after an informed consent.

Potential benefit of the MER® stent implantation will be evaluated based on angiography and duplex Doppler ultrasound examination.

Follow ups are scheduled at 30 days, 6 and 12 months after index procedure. Except for clinical follow up patients will undergo carotid vessels ultrasound examination after 6 and 12 months. In case of an emergency visit, caused by the Serious Adverse Event, Patient will undergo: neurological and cardiac evaluation as well as carotid vessels USG examination and extended CT or MRI scans.

In general, all procedures in the study will follow the local standard of care. The type of devices used during the angioplasty (including the MER® stents) will not differ from the devices used in the usual clinical practice in the hospital. DAPT and other medical therapy will be consistent with the rules of the Polish and European Society of Cardiology.

03

Conditions studied

  • Carotid Artery Stenosis

Keywords

  • carotid artery
  • stroke
  • stent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • De novo lesion located in the internal carotid artery or common carotid artery

    • DS ≥50% (nonsymptomatic patients) and ≤99% based on QCA
    • DS ≥75% (symptomatic patients) and ≤99% based on QCA
  • Target lesion available for 20-60mm lenght and 4-10mm diameter scaffold
  • Patient eligible for CAS
  • Age ≥ 18
  • Life expentancy ≥ 12 months
  • The patient's written has been obtained prior to the procedure.

Exclusion criteria

Exclusion Criteria:

  • Lack of neurological CAS qualification
  • The patient has experienced an acute myocardial infarction within 72 hours of the procedure
  • The patient has known paroxysmal, persistent or permanent atrial fibrillation or flutter
  • The patient has known gastrointestinal bleeding
  • Pregnancy
  • DAPT
  • Surgery planned within 1 month after the procedure
  • A count \<100,000/mm³ or >600,000/mm³
  • The patient has known nickel, titanium or contrast allergy
  • The target vessel is totally occluded
  • The patient has stent(s) in the target lesion
  • Statin therapy contraindications
  • The target lesion has massive calcifications
  • Hyperthyroidism
  • Post-radiotherapy side effects
  • No pulse in femoral artery
  • Chronic kidney disease (creatinine level >2,0 mg/dl or \<30 mL/min/1.73 m2 or dialysotherapy)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Patients with MER stent

    Patients eligible for Carotid Artery Stenting

    Device: MER

Interventions

  • DeviceMER

    carotid artery stenting

06

What researchers measure

Primary outcomes

  1. Stroke within 30 days after the procedure

    Stroke within 30 days after the procedure

    Time frame: 30 days

Secondary outcomes

  1. MAE

    compound Major Adverse Events (death, stroke, heart attack) within 30 days after the procedure

    Time frame: 30 days

  2. MAE

    compound Major Adverse Events (death, stroke, heart attack) within 365 days after the procedure. Restenosis (%DS ≥50%) within 365 days.

    Time frame: 365 days

  3. Target vessel revascularization within 365 days

    Target vessel revascularization within 365 days

    Time frame: 365 days

  4. Procedure success

    Procedure success (with residual stenosis ≤30%)

    Time frame: 365 days

  5. SADE

    Serious Adverse Device Effect

    Time frame: 365 days

07

Study locations

4 sites
  • Małopolskie Centrum Sercowo-Naczyniowe PAKS American Heart of Poland S.A., Oddział Chirurgii naczyniowej
    Chrzanow, 32-500, Poland
  • Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Uniwersytetu Medycznego w Katowicach, Oddział Chirurgii Ogólnej, Naczyń, Angiologii i Flebologii
    Katowice, 40-635, Poland
  • Oddział Kliniczny Chorób Serca i Naczyń Krakowski Szpital Specjalistyczny im. Jana Pawła II
    Krakow, 31-202, Poland
  • Centrum Interwencyjnego Leczenia Udaru i Chorób Naczyniowych Mózgu Instytut Psychiatrii i Neurologii
    Warszawa, 02-957, Poland
08

References and documents

Publications

  • Maciejewski D, Pieniazek P, Tekieli L, Paluszek P, Dzierwa K, Trystula M, Wojcik-Pedziwiatr M, Podolec P. Transradial approach for carotid artery stenting in a patient with severe peripheral arterial disease. Postepy Kardiol Interwencyjnej. 2014;10(1):47-9. doi: 10.5114/pwki.2014.41469. Epub 2014 Mar 23. PubMed 24799929 ↗
  • Dzierwa K, Pieniazek P, Tekieli L, Musialek P, Przewlocki T, Kablak-Ziembicka A, Kosobucka-Peszat R, Machnik R, Trystula M, Podolec P. Carotid artery stenting according to the "tailored CAS" algorithm performed in the very elderly patients: the thirty day outcome. Catheter Cardiovasc Interv. 2013 Nov 1;82(5):681-8. doi: 10.1002/ccd.25025. Epub 2013 Jul 3. PubMed 23825008 ↗
  • Pieniazek P, Tekieli L, Musialek P, Kablak Ziembicka A, Przewlocki T, Motyl R, Dzierwa K, Paluszek P, Hlawaty M, Zmudka K, Podolec P. Carotid artery stenting according to the tailored-CAS algorithm is associated with a low complication rate at 30 days: data from the TARGET-CAS study. Kardiol Pol. 2012;70(4):378-86. PubMed 22528713 ↗
  • Musialek P, Pieniazek P, Tracz W, Tekieli L, Przewlocki T, Kablak-Ziembicka A, Motyl R, Moczulski Z, Stepniewski J, Trystula M, Zajdel W, Roslawiecka A, Zmudka K, Podolec P. Safety of embolic protection device-assisted and unprotected intravascular ultrasound in evaluating carotid artery atherosclerotic lesions. Med Sci Monit. 2012 Feb;18(2):MT7-18. doi: 10.12659/msm.882452. PubMed 22293887 ↗
  • Dzierwa K, Pieniazek P, Musialek P, Piatek J, Tekieli L, Podolec P, Drwila R, Hlawaty M, Trystula M, Motyl R, Sadowski J. Treatment strategies in severe symptomatic carotid and coronary artery disease. Med Sci Monit. 2011 Aug;17(8):RA191-197. doi: 10.12659/msm.881896. PubMed 21804476 ↗
  • Pieniazek P. [A new era for the stenting of the carotid arteries in the light of the CREST study]. Kardiol Pol. 2010 Sep;68(9):1086-7. No abstract available. Polish. PubMed 20859914 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2016, a primary completion of Jun 2017 and a completion of Jun 2019. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2017
First posted
Apr 28, 2017
Start
Oct 2016
Primary completionActual
Jun 22, 2017
CompletionActual
Jun 25, 2019
Last update
Nov 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03133429
Lead sponsor
Balton Sp.zo.o.
Collaborators
KCRI
Responsible party
Sponsor
First posted
Apr 28, 2017
Start date
Oct 2016
Primary completion
Jun 22, 2017
Completion
Jun 25, 2019
Last update
Nov 19, 2019

Study contacts

Piotr Odrowąż-Pieniążek, Prof.
principal investigator · Oddział Kliniczny Chorób Serca i Naczyń Krakowski Szpital Specjalistyczny im. Jana Pawła II ul. Prądnicka 80 31-202 Kraków
Paweł Buszman, Prof.
principal investigator · I Oddział Kardiologiczno-Angiologiczny American Heart of Poland S.A. ul. Sanatoryjna 1 43-450 Ustroń

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion